Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Bruce Cozadd

Jazz Pharmaceuticals plc

Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

MOMA Therapeutics focuses on discovering the next generation of precision medicines by targeting the molecular machines underlying human disease.

MOMA Therapeutics

Mundipharma develops and delivers a range of medicines and healthcare solutions, focusing on meeting patient needs. Self-described as having a significant impact on patients.

Metric
Company Name	Jazz Pharmaceuticals plc	Fairmount Funds	MOMA Therapeutics	Mundipharma
Symbol	JAZZ
MSH ID	COM:JAZZPHARMA	COM:FAIRMOUNTFUNDS	COM:MOMATX	COM:MUNDIPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Investment Management	Biotechnology	Pharmaceuticals
Country	IE	US	US	GB
Stage			Series B
Employee Count	2.80K
Website	jazzpharma.com	fairmountfunds.com	momatx.com	mundipharma.com
LinkedIn	jazz-pharmaceuticals	fairmount-funds-management-llc
Founders

Metric
Market Cap	6.45B
Enterprise Value
Monthly Web Traffic		88	2.27K
Web Traffic Growth		-0.70	0.12
Valuation
Raised Capital			150M

Metric
Revenue	3.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.79B
EBITDA	1.30B
Operating Income	659.28M
Net Income	414.83M
EPS	6.55
Diluted EPS	6.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.85
Operating Profit Margin	0.17
EBITDA Margin	0.34
Net Profit Margin	0.11
Return on Equity	0.12
Return on Assets	0.04
Return on Capital Employed	0.07

COM:JAZZPHARMA

Cisco Systems Inc

Last Close

125.10

22/11 21:00

Market Cap

6.45B

Beta: -

Volume Today

851.93K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	95.39
P/B Ratio	2.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.03
EV Multiple	2.48

Metric
Days Sales Outstanding	60.39
Days Payables Outstanding	80.89
Days Inventory Outstanding	371.16
Operating Cycle	438.35
Cash Conversion Cycle	374.47
Asset Turnover	0.34

Metric
Operating Cash Flow	1.09B
Free Cash Flow	1.07B
Cash Flow to Debt	0.19
Operating Cash Flow/Sales	0.28
Free Cash Flow Yield	0.11

Metric
Cash & Equivalents	1.21B
Accounts Receivable	-51.88M
Inventory	597.04M
Goodwill	1.75B
Debt to Capitalization	0.61
Debt to Assets	0.52
Current Ratio	2.06
Quick Ratio	2.02

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.21
SG&A to Revenue